Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Blood rheology modulation refers to the therapeutic or experimental alteration of blood’s flow properties, namely viscosity and associated rheological factors (cellular and plasma), to improve tissue perfusion and reduce disease risk or severity[1][3][9]. Blood viscosity is determined predominantly by the concentration and deformability of red blood cells and large plasma proteins, with increased viscosity linked to cardiovascular events and vascular injury[1]. Key modulators include drugs or interventions that improve RBC deformability, reduce aggregation, or lower plasma viscosity. Though modulation of blood rheology is a valid therapeutic strategy in several diseases, "blood rheology modulation" itself is not a molecular target but a therapeutic objective or intervention principle[1][3][9].
Decreasing plasma viscosity; improving red blood cell deformability; reducing red blood cell aggregation; modifying plasma protein concentration (e.g., fibrinogen)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood rheology modulation.